DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target

Table 1 Clinicopathologic factors of high- and low-DLGAP5 expression groups in TCGA-LUAD cohort

Characteristics	Low expression of DLGAP5	High expression of DLGAP5	P value
n	269	270
Pathologic T stage, n (%)			0.002
T1	107 (20%)	69 (12.9%)
T2	126 (23.5%)	166 (31%)
T3	26 (4.9%)	23 (4.3%)
T4	8 (1.5%)	11 (2.1%)
Pathologic N stage, n (%)			< 0.001
N0	192 (36.7%)	158 (30.2%)
N1	39 (7.5%)	58 (11.1%)
N2	25 (4.8%)	49 (9.4%)
N3	0 (0%)	2 (0.4%)
Pathologic M stage, n (%)			0.084
M0	182 (46.7%)	183 (46.9%)
M1	8 (2.1%)	17 (4.4%)
Clinical stage, n (%)			0.001
Stage I	168 (31.6%)	128 (24.1%)
Stage II	57 (10.7%)	68 (12.8%)
Stage III	30 (5.6%)	54 (10.2%)
Stage IV	9 (1.7%)	17 (3.2%)
Primary therapy outcome, n (%)			< 0.001
PD	20 (4.5%)	51 (11.4%)
SD	23 (5.1%)	15 (3.3%)
PR	4 (0.9%)	2 (0.4%)
CR	181 (40.3%)	153 (34.1%)
Gender, n (%)			0.002
Female	162 (30.1%)	127 (23.6%)
Male	107 (19.9%)	143 (26.5%)
Race, n (%)			0.350
Asian	6 (1.3%)	2 (0.4%)
Black or African American	30 (6.4%)	25 (5.3%)
White	207 (43.9%)	202 (42.8%)
Age, n (%)			0.023
< = 65	117 (22.5%)	140 (26.9%)
> 65	146 (28.1%)	117 (22.5%)
Smoker, n (%)			0.020
No	48 (9.1%)	29 (5.5%)
Yes	215 (41%)	233 (44.4%)
Number pack years smoked, n (%)			0.010
< 40	102 (27.6%)	86 (23.3%)
> = 40	74 (20.1%)	107 (29%)
OS event, n (%)			< 0.001
No	194 (36%)	153 (28.4%)
Yes	75 (13.9%)	117 (21.7%)
DSS event, n (%)			< 0.001
No	209 (41.6%)	174 (34.6%)
Yes	44 (8.7%)	76 (15.1%)
PFI event, n (%)			0.001
No	175 (32.5%)	138 (25.6%)
Yes	94 (17.4%)	132 (24.5%)

PD, Progressive Disease; SD, stable disease; PR, partial response; CR, complete response; OS, overall survival; DSS, disease-specific survival; PFI, progression-free interval

ISSN: 1479-5876